Alzamend Neuro Inc. released its financial results for the fiscal year ending April 30, 2025. The company reported a net loss attributable to common shares of approximately $4.99 million, a decrease from the previous year's net loss of about $9.95 million, reflecting a 49.9% improvement. Total operating expenses were $4.50 million, down 55% from $9.94 million the prior year. Research and development expenses significantly decreased by 78% to $1.41 million from $6.46 million, while general and administrative expenses also saw a reduction of 12% to $3.08 million from $3.48 million. The company's product candidates, AL001 and ALZN002, remain in the clinical stage of development, requiring further study, evaluation, and regulatory approval before generating revenue. Alzamend Neuro Inc. continues to advance the clinical development of AL001 for the treatment of Alzheimer's, BD, MDD, and PTSD, as well as ALZN002 for Alzheimer's treatment. The company is also focused on expanding its pipeline of pharmaceuticals to include additional indications and delivery methods for AL001.